Quick answer: GHK-Cu, commonly called copper peptide, is a naturally occurring copper-binding tripeptide found in human plasma at levels that decline with age. Most of the research behind it comes from cell culture and animal models, with a smaller set of human studies on topical cosmetic formulations applied to the skin. Injectable GHK-Cu has essentially no controlled human trial evidence behind it and is not an FDA-approved drug. Everhuman does not offer GHK-Cu, and this page exists only to explain what the research does and does not show.
Copper peptide is the everyday name for GHK-Cu, a short chain of three amino acids, glycine, histidine and lysine, bound to a copper ion. GHK was first isolated from human plasma in the early 1970s, and researchers noticed that plasma concentrations appear to fall substantially between young adulthood and later life. Much of the interest since then has followed from that single observation: a molecule the body already makes, present in smaller amounts as people age.
What GHK-Cu actually is
GHK-Cu is a tripeptide, which places it among the smallest molecules people describe as peptides. Copper binds to the histidine residue with high affinity, and the copper-bound form is the one most of the literature studies. If you want the general category background before going further, the explainer on what peptides are and how they differ from proteins covers the vocabulary this page assumes.
How the mechanism is described in the research
GHK-Cu is described in the literature mainly as a signalling molecule rather than a structural one. Cell culture work reports that it influences the expression of genes involved in extracellular matrix turnover, including collagen and glycosaminoglycan production by fibroblasts, and that it participates in copper transport between cells. Copper itself is a required cofactor for several enzymes involved in connective tissue cross-linking, which gives the copper-bound form a plausible reason to matter.
Mechanism, though, is the cheapest part of any peptide story. A molecule that changes gene expression in a dish of fibroblasts has demonstrated that it can do something in that dish, not that applying it to a person produces a clinically meaningful result. The guide on how to read peptide evidence without being misled walks through why mechanism claims and outcome claims are different categories of statement.
What the human evidence covers, and what it does not
Human evidence for GHK-Cu is concentrated almost entirely in dermatology and cosmetics. Several small controlled studies have tested copper peptide creams and serums applied to facial or forearm skin, reporting changes in measures such as skin density, fine line appearance and, in some studies, biopsy findings. Sample sizes tend to be modest, follow-up short, and a number of the studies were funded by companies selling the formulations, all of which are ordinary reasons for caution rather than reasons for dismissal.
Wound repair is the other area with human data, largely from older work on copper peptide preparations applied to surgical or chronic wounds. Results in that literature are mixed and the trials are generally small. Outside of skin, the human record thins out to almost nothing.
Systemic effects are where the gap becomes obvious. Claims that GHK-Cu supports lung tissue, nerve tissue, liver tissue or general recovery trace back overwhelmingly to rodent studies, cell models and gene-expression analyses rather than to human trials. No controlled human study establishes that injected GHK-Cu produces those systemic outcomes in people.
Topical versus injectable, which is the whole argument
Topical and injectable GHK-Cu are usually discussed as if they were the same product, and they are not. The human evidence that exists sits almost entirely on the topical side, in cosmetic formulations regulated as cosmetics rather than as drugs. Marketing frequently borrows the credibility of that topical research to sell an injectable version that the research never tested.
Injected GHK-Cu also introduces questions topical use does not raise. Copper is an essential trace mineral with a defined range of tolerance, and delivering a copper complex systemically raises reasonable questions about copper load, sterility and formulation quality that a cream applied to the forearm simply does not. None of that is settled by the topical literature.
Regulatory status and where copper peptide is sold
Copper peptide occupies two different regulatory positions depending on the form. As a cosmetic ingredient in creams and serums, GHK-Cu is sold openly and legally in the United States, and the products are regulated as cosmetics, meaning they are not evaluated for drug claims. As an injectable, GHK-Cu is not an FDA-approved drug and is not part of the licensed prescription system in the way an approved medication is.
Injectable copper peptide is therefore usually found in the grey market, sold as material labelled for laboratory research rather than dispensed through a licensed pharmacy after a clinical evaluation. The difference between those two supply routes is explained in more detail in the comparison of research-labelled peptides and prescription products, and it is the single most important distinction in this category.
How to read copper peptide marketing
Copper peptide marketing tends to follow a recognisable pattern worth naming. A real finding from cell culture is described in language that sounds like a clinical result, the age-related decline in plasma GHK is presented as a deficiency requiring correction, and topical study data is quietly attached to an injectable product. Each step is small, and the finished claim is far ahead of the evidence.
Reading the sourcing carefully is the practical defence. Ask whether a cited study was in humans or animals, whether the route of administration matches the product being sold, and whether the outcome measured is the outcome being promised. If a seller cannot answer those three questions from the studies they cite, the claim is marketing rather than evidence, and the checklist for verifying whether a peptide provider is legitimate is the right next step.
Frequently Asked Questions
Is copper peptide the same as GHK-Cu?
Copper peptide is the common consumer name for GHK-Cu, so in most contexts the two terms refer to the same molecule. GHK is the tripeptide glycyl-histidyl-lysine, and GHK-Cu is that tripeptide bound to a copper ion. Some cosmetic products use related copper complexes and still market themselves as copper peptides, so the label is looser than the chemical name.
Does copper peptide work for skin?
Topical copper peptide has the strongest human evidence of any use, and several small controlled studies report measurable changes in skin appearance and density. Those studies are limited by small sample sizes, short duration and frequent industry funding, so the honest description is suggestive rather than settled. Copper peptide is not an approved medical product for any skin condition.
Is injectable copper peptide studied in humans?
Injectable GHK-Cu has essentially no controlled human trial evidence supporting the systemic benefits it is marketed for. The systemic claims come from rodent studies and cell culture work, which describe biological activity rather than clinical outcomes in people. Anyone presenting topical study results as support for an injectable product is stretching the evidence past what it covers.
Is GHK-Cu legal in the United States?
GHK-Cu is legal to sell as a cosmetic ingredient in topical products, and those products are widely available. Injectable GHK-Cu is not an FDA-approved drug, and material sold as research chemical is not intended or permitted for human use. The broader picture is covered in the overview of how peptide legality works in the United States.
Why do plasma GHK levels fall with age?
Plasma GHK concentrations have been reported to decline substantially between early adulthood and later decades, though the reasons are not fully established. An age-related decline in a naturally occurring molecule is a common observation across many biological systems and does not by itself demonstrate that restoring the molecule changes health outcomes.
Does Everhuman offer copper peptide?
Everhuman does not offer GHK-Cu in any form. This reference page exists because copper peptide is heavily marketed and poorly explained, and a straight account of the evidence is useful whether or not anyone is selling it.
The honest summary
GHK-Cu is one of the more genuinely interesting molecules in this category, with a real biological pedigree and a substantial body of laboratory work behind it. Human evidence, however, is concentrated in topical skin applications, is limited in size and quality, and does not extend to the systemic effects that injectable products are sold on.
Interesting mechanism, thin human evidence, and mostly sold outside the licensed system is the accurate summary, and it is worth holding all three parts at once. Before considering anything in this category, the overview of what is known about peptide side effects and tolerability is a reasonable place to continue reading.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
The human tri-peptide GHK and tissue remodeling. Journal of biomaterials science. Polymer edition. 2008. PMID 18644225.
Expression and activation of matrix metalloproteinases in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. The Journal of investigative dermatology. 1999. PMID 10383745.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.